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Hepatic artery embolisation is a well-documented method in the treatment of patients with disseminated midgut caranoid tumours. After embolisation, an increased urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) indicates tumour cell necrosis with subsequent release of serotonin (5-Hi) (Ahlman et al., 1991) . In previous studies, embo}isation therapy has been instituted to obtain symptom relief at a late stage of the disease and thus added little to survival (Coupe et al., 1989) . At our unit all patients with bilobar hepatic metastases during the last 6 years have undergone embolisation subsequent to prinary surgery, with octreotide as adjuvant therapy (200 jg s.c. daily). In a follow-up study of the therapeutic resonse it was shown that the patients could be divided into two groups: (I) responders with more than 50% tumour reduction, evaluated by computeried tomography (CT) 3 months post embolisation, and a pronounced reduction in 5-HAA excretion (80 ± 3%); (II) non-responders with less than 50% tumour reduction, or progressive disease, and a moderate 5-HAA reduction (28 ± 12%). The first group of patients had a therapeutic response of much longer duration (Wingberg et al., 1993 Hermodsson, 1987 Hermodsson, , 1993 (Hellstrand and Hermodsson, 1993) . The NK cell-mediated cytotoxicity of MNC was analysed using K562 erythrokeukaemic target cells as described in detail previously (Helltrand and Hermodsson, 1987 relation to number of NK cells was not changed after embolisation (data not shown), indicating that the NK cells recruited after embolisation were functionally similar to the pre-existing population in peripheral blood. When evaluated biochemically and radiologically 3 months post embolisation, six patients were classified as responders and five as non-responders. The accumulation of NK cells and the clinical response seemed to be related, except in one patient with rapidly progressive extrahepatic disease ( Figure  2 ). Interestingly, in contrast to all other patients, CD3+/56+ cells accumulated (9.0-25.8%) in this patient in parallel with the accumulation of NK cells (14.5-31.3% 
